1Pool PE. The clinical significance of neurohormonal activation. ClinTher, 1997, 19,Suppl A:53.
2Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol producesdose-related improvements in left ventricular function and survival insubjects with chronic heart failure. MOCHA Investigators. Circula-tion, 1996,94(11):2807.
3The Cardiac Insufficiency Bisoprolol Study Ⅱ ( CIBIS- Ⅱ ): a ran-domized trial. Lancet, 1999,353(9146):9.
4MERIT-HF Study Group. Effect of metoprolol CR/XL in chronicheart failure. Lancet, 1999,353(9169) :2001.
5Eichhorn EJ, Stevenson LW. The ten most commonly asked ques-tions about Beta-Blockers for heart failure. Cardiol Rev, 1998,6(2):59.
6Willenheimer R. Left ventricular remodelling and dysfunction. Canthe process be prevented? Int J Cardiol, 2000,72(2): 143.
7Fagerberg B. The merit of beta(1)-blockade in heart failure. EurHeart J, 1999,20(24):1761.
